Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.
about
CARs in chronic lymphocytic leukemia -- ready to driveVirus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaDifferentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells.Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytesCombining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.T cells redirected against CD70 for the immunotherapy of CD70-positive malignanciesThe promise and potential pitfalls of chimeric antigen receptors.In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.Genetically modified T-cell therapy for osteosarcomaThe past, present, and future of adoptive T cell therapy.Enhancing siRNA effects in T cells for adoptive immunotherapy.Supernatural T cells: genetic modification of T cells for cancer therapy.Cellular therapies in acute lymphoblastic leukemiaRedirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategiesAntibody-based therapeutics for the treatment of human B cell malignanciesGenetic modification of T cells for immunotherapy.Adoptive cellular immunotherapy for childhood malignancies.Targeting T cells with bispecific antibodies for cancer therapyT lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.Immunotherapy targeting EBV-expressing lymphoproliferative diseasesDesign and development of therapies using chimeric antigen receptor-expressing T cellsTreatment of lymphoma with adoptively transferred T cells.Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunityCD19-CAR trials.Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.Cellular immunotherapy for high-grade glioma.Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.T cells as vehicles for cancer vaccinationGenetic engineering of T cells for the immunotherapy of haematological malignancies.Adoptive immunotherapy of cancer: Gene transfer of T cell specificity.Genetically modified T cells to target glioblastoma.Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.
P2860
Q26830526-3B3833AE-A06D-4162-BE44-165D329A0C2CQ29622835-23B34985-52D4-4FB3-AD8E-9BD47CC88F9BQ30479628-042388E0-23DD-47D4-B10E-093CA8A8E162Q30584839-F4BAAA8C-CD0B-47BA-B337-CD929141A575Q33791998-7A208598-D420-487B-8388-F85A3198ACD3Q33862876-E8ADF78B-71AB-4FB1-8CBD-3F964A0AE01BQ34122292-32E8638D-51CF-441C-B763-838FF1CB988FQ34923799-1F23A520-20B7-41F7-91E0-FBAA9D19A37FQ34970378-F97FCFEF-D556-4F13-B043-B58305D0B8DCQ35001579-B2766997-096F-4765-BF62-7AB243C73DFBQ35142912-DABB4F55-E42B-43DD-BA93-9AC07A00BCEFQ35811921-6C498C56-16CC-4DA1-B306-BB4B96EBFA74Q36007685-AD7BABC2-19B6-4B3A-BF0B-91697A9BAD77Q36057568-8110032E-3846-44C5-A413-6BD144D1F22EQ36198232-423CDD20-618B-461D-879E-0DFCB985A39DQ36306644-DA952933-0D4E-40B8-9345-0DF37567262AQ36328391-67D29B64-A560-40BE-9564-7A64758DD442Q36328805-C418EB8B-7B3B-4830-B60A-214772BCC447Q36552098-9C37E5A2-BB4A-4A06-AE02-50D14DCCFE8CQ36713904-5E8AE2BF-8B2C-41C3-BE92-7839BE1128E8Q36819337-72743C27-C724-455A-B0D2-EBB33B946AEAQ36907540-A66E598A-404B-47F1-A96E-26565410E7E2Q36909362-1DD8C9A7-6A09-41C4-8610-5C81D7815E6EQ37008216-E5FEBC28-FCA5-4E01-841C-2328F2284CABQ37220742-311567DF-C19F-488C-9657-91CDA7FBFAC8Q37262424-46EB067B-3776-4B3C-93F8-3DA8F8D65465Q37268305-5C9A3EF5-C061-4765-A705-958B5E7BAB68Q37418289-6E82B071-1CDC-4BA3-8B5F-2E4767638987Q37419728-3C33CDF2-5334-4E3F-8D2A-6FC9B899A16FQ37469199-00BBB3B8-21EB-405B-B7E2-8B1E982308FAQ37692134-79D421C0-D433-4C86-96E4-2DA901541F8FQ37793222-10157386-218C-4A61-9894-4F7A213EFB5AQ37851972-5298C42C-AACC-4B3D-AE03-E24AE2182E50Q37861192-32649C9E-81D7-4C83-9A79-1FF8CD1F4BA1Q37952805-5D66061E-7B77-436E-95BA-767D8E71AC44Q37963343-E980EB72-0685-4EA3-969C-A336B8F35340Q37965815-60820D7A-822B-4580-820C-A9F8812E4898Q37980749-0CB2CB1A-2274-4868-971A-62F170814816Q38178690-B7810FA8-3CD3-4B25-BDFB-96087899E757Q38319552-66E05E40-E298-46CB-A994-92B2C833A4A1
P2860
Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Enhanced antilymphoma efficacy ...... fied to present influenza MP1.
@en
type
label
Enhanced antilymphoma efficacy ...... fied to present influenza MP1.
@en
prefLabel
Enhanced antilymphoma efficacy ...... fied to present influenza MP1.
@en
P2093
P1433
P1476
Enhanced antilymphoma efficacy ...... fied to present influenza MP1.
@en
P2093
Adrian Castro
Laurence J N Cooper
Lisa Marie Serrano
Michael C Jensen
Sergio Gonzalez
Simon Olivares
Stephen J Forman
Timothy Pfeiffer
Wen-Chung Chang
Zaid Al-Kadhimi
P304
P356
10.1182/BLOOD-2004-03-1208
P407
P577
2004-10-26T00:00:00Z